The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
A study presented at the annual meeting of the American Geophysical Union in December 2006 asserted that a small-scale regional nuclear war could produce as many direct fatalities as all of World War II and disrupt the global climate for a decade or more. In a regional nuclear conflict scenario in which two opposing nations in the subtropics each used 50 Hiroshima-sized nuclear weapons (c. 15 kiloton each) on major population centers, the researchers predicted fatalities ranging from 2.6 million to 16.7 million per country. The authors of the study estimated that as much as five million tons of soot could be released, producing a cooling of several degrees over large areas of North America and Eurasia (including most of the grain-growing regions). The cooling would last for years and could be "catastrophic", according to the researchers. Either a limited or full-scale nuclear exchange could occur during an accidental nuclear war, in which the use of nuclear weapons is triggered unintentionally. Postulated triggers for this scenario have included malfunctioning early warning devices and/or targeting computers, deliberate malfeasance by rogue military commanders, consequences of an accidental straying of warplanes into enemy airspace, reactions to unannounced missile tests during tense diplomatic periods, reactions to military exercises, mistranslated or miscommunicated messages, and others. A number of these scenarios actually occurred during the Cold War, though none resulted in the use of nuclear weapons.
The new department was financed by a US $12-million gift from Bill Gates, who shared Hood's interest in combining biological research and computer technology and applying them to medical research. Roger Perlmutter, who had worked in Hood's lab at Caltech before moving to UW as chair of the immunology department, played a key role organizing his recruitment to UW. Hood and other scientists from Caltech's NSF center moved to the University of Washington during 1992-1994, where they received renewed support from the NSF as the Center for Molecular Biotechnology. (Later, in 2001, the department of molecular biotechnology and the genetics department at UW reorganized to form the department of genome sciences.) In 2000 Hood resigned his position at the University of Washington to become co-founder and president of the non-profit Institute for Systems Biology (ISB), possibly the first independent systems biology organization. His co-founders were protein chemist Ruedi Aebersold and immunologist Alan Aderem. Hood is still an affiliate professor at the University of Washington in Computer Science, Bioengineering and Immunology. In April 2017, the ISB announced that Hood will be succeeded as president of ISB as of January 2018 by James Heath, while continuing to lead his research group at ISB and serving on ISB's board of directors. Hood believes that a combination of big data and systems biology has the potential to revolutionize healthcare and create a proactive medical approach focused on maximizing the wellness of the individual. He coined the term "P4 medicine" in 2003.
In 1937, the administration of BST was shown to increase the milk yield in lactating cows by preventing mammary cell death in dairy cattle. Until the 1980s, use of the compound was very limited in agriculture as the sole source of the hormone was from bovine carcasses. During this time, the knowledge of the structure and function of the hormone increased. With the advent of biotechnology, one of the pioneering biotech companies, Genentech, in 1981 succeeded in cloning and patenting the gene for BST. Monsanto had been working along the same lines and struck a deal with Genentech in 1979 to license Genentech's patents and collaborate on development of a recombinant version of BST – a process on which Monsanto would invest $300 million. The two companies used genetic engineering to clone the BST gene into E. coli. The bacteria are grown in bioreactors, then broken up and separated from the rBST, which is purified to produce the injectable hormone. They published their first field trial results in 1981. Lilly, American Cyanamid, Upjohn, and Monsanto all submitted applications to market rBST to the FDA, and the FDA completed its review of the human safety component of these applications in 1986 and found food from rBST-treated cows to be safe; however, strong public concern led to calls for more studies, investigations, and public discussions, which included an unprecedented conference on the safety of rBST in 1990 organized by the National Institutes of Health at the request of Senator Patrick Leahy. FDA approved Monsanto's application in 1993.
== Bibliography == Barkawi, Tarak (April 2006). "Culture and Combat in the Colonies: The Indian Army In the Second World War". Journal of Contemporary History. 41 (2). Sage: 325–355. doi:10.1177/0022009406062071. S2CID 145364543. Barthorp, Michael (2002). Afghan Wars and the North-West Frontier 1839–1947. London: Cassel. ISBN 0-304-36294-8. Barua, Pradeep (2003). Gentlemen of the Raj: The Indian Army Officer Corps, 1817–1949. Westport, CT: Praegar. ISBN 0275979997. Chandler, David (2002). Oxford History of the British Army (2nd ed.). USA: Oxford University Press. ISBN 0192803115. Gaylor, John (1996). Sons of John Company – The Indian & Pakistan Armies 1903–1991. Tunbridge Wells, Kent: Parapress. ISBN 1-898594-41-4. Haythornthwaite, P.J. (1992). The World War One Sourcebook. Arms and Armour Press. Heathcote, T. A. (1974). The Indian Army – The Garrison of British Imperial India, 1822–1922. Newton Abbot, Devon: David & Charles. Ilbert, Courtenay (1 January 1913). "British India". Journal of the Society of Comparative Legislation. 13 (2): 327–333. JSTOR 752287. Imperial Gazetteer of India, Volume IV (1908). Indian Empire: Administrative. Oxford: Clarendon Press. p. 552. Jackson, Donovan (1940). India's Army. London: Sampson Low. Lapping, Brian (1985). End of Empire. London: Guild Publishing. Mazumder, Rajit K. (2003). The Indian army and the making of Punjab. Delhi, India: Permanent Black. ISBN 8178240599. Nathan, R.; Lee-Warner, William; Carnduff, H. W. C.; Maclagan, E. D.; Walker, G. H. D.; Collen, Edwin; Nathan; Bythel, W. J.; Hemming, T. H. (1908).
=== Polygamy === Both male and female D. melanogaster flies act polygamously (having multiple sexual partners at the same time). In both males and females, polygamy results in a decrease in evening activity compared to virgin flies, more so in males than females. Evening activity consists of those in which the flies participate other than mating and finding partners, such as finding food. The reproductive success of males and females varies, because a female only needs to mate once to reach maximum fertility. Mating with multiple partners provides no advantage over mating with one partner, so females exhibit no difference in evening activity between polygamous and monogamous individuals. For males, however, mating with multiple partners increases their reproductive success by increasing the genetic diversity of their offspring. This benefit of genetic diversity is an evolutionary advantage because it increases the chance that some of the offspring will have traits that increase their fitness in their environment. The difference in evening activity between polygamous and monogamous male flies can be explained with courtship. For polygamous flies, their reproductive success increases by having offspring with multiple partners, and therefore they spend more time and energy on courting multiple females. On the other hand, monogamous flies only court one female, and expend less energy doing so. While it requires more energy for male flies to court multiple females, the overall reproductive benefits it produces has kept polygamy as the preferred sexual choice.
Sources: en.wikipedia.org
The opioid epidemic now involves more overdose deaths with both opioids and cocaine, especially among non-Hispanic Blacks who are twice as likely to die from combined opioid-stimulant overdoses compared to non-Hispanic whites. Cocaine-related deaths in Blacks are similar to opioid deaths in whites. Risk factors include young age, education, urban living, mental disorders, and stress. It remains unclear if co-use is intentional. Recent studies expand focus beyond heroin to all opioids, reflecting changing overdose patterns.
=== Pavlopetri === Ceramic petrography has also been used in underwater locations, where excavations and analysis of remains can prove far more challenging. For example, in the submerged city of Pavlopetri (C. 3500 – 1500BCE) scientists have used petrography to examine the mineralogical make-up and microstructure of underwater pottery, allowing archaeologists to gain an insight into the trade routes, production methods, and various other cultural practices that the inhabitants of Pavlopetri adopted. From this analysis, scholars have been able to link Pavlopetri to trade in Minoan Crete.
Prolonged exposure to dry ice can cause severe skin damage through frostbite, and the fog produced may also hinder attempts to withdraw from contact in a safe manner. Because it sublimes into large quantities of carbon dioxide gas, which could pose a danger of hypercapnia, dry ice should only be exposed to open air in a well-ventilated environment. For this reason, in the context of laboratory safety dry ice is assigned label precaution P403: "Store in a well-ventilated place." Industrial dry ice may contain contaminants that make it unsafe for direct contact with food. Tiny dry ice pellets used in dry ice blast cleaning do not contain oily residues. Dry ice is assigned a UN number, a code for hazardous substances: UN 1845. Dry ice is not classified as a dangerous substance by the European Union, or as a hazardous material by the United States Department of Transportation for ground transportation. However, in the US, it is regulated as a dangerous good when shipped by air or water. International Air Transport Association (IATA) regulations require specific diamond-shaped black-and white labelling to be placed on the package. The package must have adequate ventilation so that it will not rupture from pressure in the event that the Dry Ice begins to sublime in the packaging. The Federal Aviation Administration in the US allows airline passengers to carry up to 2.5 kg (5.5 lb) per person either as checked baggage or carry-on baggage, when used to refrigerate perishables.
Modern kefir is made by adding kefir grains to milk typically at a proportion of 2–5% grains-to-milk. The mixture is then placed in a corrosion-resistant container, such as a glass jar, and stored preferably in the dark to prevent degradation of light-sensitive vitamins. After a period between 12 and 24 hours of fermentation at mild temperature, ideally 20–25 °C (68–77 °F), the grains are strained from the milk using a corrosion-resistant (stainless steel or plastic) utensil and kept to produce another batch. During the fermentation process the grains enlarge and eventually split forming new units. The resulting fermented liquid may be drunk, used in recipes, or kept aside in a sealed container for additional time to undergo a secondary fermentation. Because of its acidity the beverage should not be stored in reactive metal containers such as aluminium, copper, or zinc, as these may leach into it over time. The shelf life, unrefrigerated, is up to thirty days. The Russian method permits production of kefir on a larger scale and uses two fermentations. The first step is to prepare the cultures by inoculating milk with 2–3% grains as described. The grains are then removed by filtration and 1–3% of the resulting liquid mother culture is added to milk and fermented for 12 to 18 hours. Kefir can be made using freeze-dried cultures commonly available in powder form from health food stores. A portion of the resulting kefir can be saved to be used a number of times to propagate further fermentations but ultimately does not form grains.
Sources: en.wikipedia.org
rhEPO has been used illicitly as a performance-enhancing drug. It can often be detected in blood, due to slight differences from the endogenous protein; for example, in features of posttranslational modification.
=== Hearing === In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, requires a more prominent warning of the potential risk of sudden hearing loss as the result of post-marketing reports of deafness associated with use of PDE5 inhibitors.
Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications. The complications of diabetes can dramatically impair quality of life and cause long-lasting disability. Overall, complications are far less common and less severe in people with well-controlled blood sugar levels. Some non-modifiable risk factors such as age at diabetes onset, type of diabetes, gender, and genetics may influence risk. Other health problems compound the chronic complications of diabetes such as smoking, obesity, high blood pressure, elevated cholesterol levels, and lack of regular exercise. Complications of diabetes are a strong risk factor for severe COVID-19 illness.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.